Testicular germ cell tumors (TGCT) have been expected to have a strong underlying genetic component. We conducted a genome-wide scan among 277 TGCT cases and 919 controls and found that seven markers at 12p22 within KITLG (c-KIT ligand) reached genome-wide significance (P o 5.0 Â 10 À8 in discovery). In independent replication, TGCT risk was increased threefold per copy of the major allele at rs3782179 and rs4474514 (OR ¼ 3.08, 95% CI ¼ 2.29-4.13; OR ¼ 3.07, 95% CI ¼ 2.29-4.13, respectively). We found associations with rs4324715 and rs6897876 at 5q31.3 near SPRY4 (sprouty 4; P o 5.0 Â 10 À6 in discovery). In independent replication, risk of TGCT was increased nearly 40% per copy of the major allele (OR ¼ 1.37, 95% CI ¼ 1.14-1.64; OR ¼ 1.39, 95% CI ¼ 1.16-1.66, respectively). All of the genotypes were associated with both seminoma and nonseminoma TGCT subtypes. These results demonstrate that common genetic variants affect TGCT risk and implicate KITLG and SPRY4 as genes involved in TGCT susceptibility.
In the United States, testicular germ cell tumors (TGCT) are the most common cancers in young men, with a peak incidence among those aged 25 to 34 years 1 . The age-adjusted incidence in white men has doubled since 1975 and is now 6.6 per 100,000. The incidence in white non-Hispanic men is nearly fivefold higher than among black men 1 . The reasons for the increasing incidence and racial disparity in TGCT rates are unknown.
Although environmental exposures have been postulated to have a role in the increasing incidence of TGCT, there also is evidence for a substantial genetic contribution to TGCT susceptibility. Brothers of individuals with TGCT have an 8-to 12-fold increased risk of disease, with the risk to monozygotic and dizygotic twins 75-and 35-fold increased, respectively, and fathers of affected individuals have a fourfold increased risk 2, 3 . Consistent with the high familial risks compared to most other cancer types and the ancestry-related differences in TGCT risk, the proportion of TGCT susceptibility accounted for by genetic effects is estimated at 25%, and TGCT has the third highest heritability among all cancers 4 .
Results from linkage studies and candidate gene approaches, however, have produced limited insight into TGCT susceptibility factors. An initial report of linkage on Xq27 was not replicated nor have other loci been identified with significant effects, which suggests that multiple loci, potentially of weak to moderate effect, contribute to disease susceptibility 5, 6 . The gr/gr deletion on the Y chromosome, studied as a candidate region, increases TGCT risk two-to threefold, but carriage frequency of this variant is low (2-3%), suggesting that it likely accounts for only a small component of risk 7 . Thus, despite the multiple lines of evidence suggesting a genetic etiology of TGCT, no genetic risk factor has been identified that can explain an appreciable proportion of TGCT cases.
To identify genes associated with TGCT development, we conducted a genome-wide association study. Cases were 277 white, non-Hispanic men with pathologically defined TGCT seen at the University of Pennsylvania Health System (UPHS) or Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania. We genotyped DNA extracted from venous blood using the Affymetrix GenomeWide Human SNP Array 6.0. We compared the frequency of observed genotypes among TGCT cases to those available from 919 white, non-Hispanic males from the Philadelphia region genotyped on the same Affymetrix platform ( Table 1) . Supplementary Figure 1 online shows the quantile-quantile plot of w 2 values for observed versus expected allele frequencies based on Fisher's exact test for the 611,254 markers meeting quality control criteria, indicating little evidence of population stratification and evidence of excess disease associations 8 . The calculated genomic control inflation (l) factor was 0.944, and hence we report unadjusted test statistics 9 .
Eight markers reached statistical significance at a genome-wide threshold of P o 5.0 Â 10 À8 (Fig. 1 and Supplementary Table 1 online). Seven of these (rs995030, rs1352947, rs1472899, rs3782179, rs3782181, rs4474514, rs11104952), including the most significant association (P ¼ 3.54 Â 10 À10 ) at rs4474514, occurred within the KITLG (c-KIT ligand) gene region on 12q22 ( Supplementary Fig. 2 online). These markers were in strong linkage disequilibrium (LD) with each other; pairwise D and r 2 measures were all 40.99 (Fig. 2a) . The eighth marker (rs3770112, P ¼ 4.93 Â 10 À8 ) mapped to the integrin alpha 4 (ITGA4) gene on 2q31.3. Because no other markers in this genomic region (±10 Mb) reached statistical significance at P o 1.0 Â 10 À3 , we suspected that this association might have arisen purely by chance. We further investigated this possibility by imputing genotypes near rs3770112 on the basis of publicly available HapMap genotypic data 10 . After imputation, the test of association at rs3770112 no longer surpassed the genome-wide threshold (P ¼ 0.05); as well, all other markers in the region remained below the threshold for advancing to replication. The correlation between observed and imputed P values for the 23 markers that were in the same LD block with rs3770112 was very high (r ¼ 0.96), and information content and maximum posterior call probability for rs3770112 were both 40.998. Taken together, these results strongly suggested that the association observed in the discovery phase was a false positive ( Supplementary  Fig. 3a ,b online). We selected two markers in KITLG (rs3782179, rs4474514) to bring forward into replication.
Sixteen additional markers reached statistical significance at the P o 5.0 Â 10 À6 level (Supplementary Table 1 ). Of these, three (rs12521013, rs4324715, rs6897876) mapped 2.4 kb downstream of the SPRY4 (sprouty homolog 4) coding region on 5q31.3 ( Fig. 2b and Supplementary Fig. 4 online), and two (rs17031166, rs1549383) mapped to a gene-free region on 2p14 that is 500 kb centromeric of SPRED2 (sprouty-related, EVH1 domain containing 2) (Supplementary Fig. 3a) . As both SPRY4 and SPRED2 have been implicated in the KIT-KITLG signaling pathway 11, 12 , and as these two regions were the only ones that contained more than one marker surpassing threshold significance, we also chose two markers at each of these loci (SPRY4: rs4324715, rs6897876; 2p14: rs17031166, rs1549383) to bring forward for replication.
The replication set consisted of a population-based set of 371 TGCT cases and 860 controls, all white non-Hispanic, recruited from residents of the metropolitan Seattle-Puget Sound region, and parents of 204 of the cases. We observed associations with rs3782179 (P trend ¼ 5.88 Â 10 À15 ) and rs4474514 (P trend ¼ 5.88 Â 10 À15 ) in KITLG and with rs4324715 (P trend ¼ 6.77 Â 10 À4 ) and rs6897876 (P trend ¼ 3.67 Â 10 À4 ) proximal to SPRY4 ( Figure 1 Genome-wide association results plotted for 277 TGCT cases and 919 controls. The threshold for genome-wide significance was P o 5.0 Â 10 À8 (top red line) based on Fisher's exact test. Markers that reached significance at P o 5.0 Â 10 À6 (bottom green line) based on Fisher's exact test also were considered.
We noted weaker associations for the two markers close to SPRY4. TGCT risk was increased nearly 40% per copy of the major T allele in rs4324715 (OR ¼ 1.37, 95% CI ¼ 1.14-1.64) and major C allele in rs6897876 (OR ¼ 1.39, 95% CI ¼ 1.16-1.66); and risk was increased 65-80% with homozygous carriage of the major alleles (OR ¼ 1.81, 95% CI ¼ 1.26-2.58; and OR ¼ 1.68, 95% CI ¼ 1.17-2.42, respectively) compared with homozygous carriage of their corresponding minor alleles. In addition to the case-control analysis, we conducted a case-parent triad analysis, which also showed that carriage of the risk allele for the markers in KITLG and proximal to SPRY4 is associated with TGCT. The per-allele relative risks (RR) for rs3782179 and rs4474514 (KITLG) were 2.5 (95% CI ¼ 1.6-0.9) and 2.6 (95% CI ¼ 1.6-4.0), respectively, and for rs4324715 and rs6897876 (proximal to SPRY4) 1.5 (95% CI 1.2, 2.1) and 1.5 (95% CI 1.1, 2.0), respectively. These family-based estimates provide additional evidence that population stratification did not bias results in the replication phase.
We did not observe an interaction between KITLG and SPRY4 marker genotypes. In the replication set, marker genotypes in KITLG and SPRY4 were associated with both seminoma and nonseminoma germ cell tumors without indication that genotype associations differed between the two subtypes ( Table 3) . In subgroup analyses among those without a family history of TGCT and among those without cryptorchidism, two strong and well-established risk factors for TGCT, the genotypic ORs associated with KITLG and SPRY4 markers were only negligibly attenuated (data not shown). These findings indicate that for most cases, KITLG and SPRY4 do not exert their effect solely through mechanisms involving these known risk factors. Because of limited numbers, it was not possible to examine the effect of KITLG and SPRY4 among those with positive family history or personal history of cryptorchidism.
We have identified variation at 12q22 as a major risk locus for TGCT susceptibility. For rs3782179 and rs4474514, we observed a threefold increased risk of disease per major allele and a 4.5-fold increased risk of disease for homozygous carriage of the major allele. The identified region contains KITLG, also known as stem cell factor, encoding the ligand for the receptor tyrosine kinase, c-KIT. The KITLG-KIT signaling pathway has an important role in gametogenesis, hematopoesis and melanogenesis 13 . In mouse models, Kitl (encoded at the steel (Sl) locus) is required for multiple aspects of primordial germ cell (PGC) development, including proliferation, migration and survival 14, 15 . Kitl has a crucial role in the migration of PGCs from the hindgut and subsequent targeting to the genital ridges, and downregulation of Kitl in the midline triggers localized apoptosis of PGCs 15 . Given the similarity in cellular ultrastructure, patterns of imprinting and gene expression, multiple human studies have suggested that TGCT arises from PGCs 16 . Delayed differentiation of PGCs has been associated with development of testicular germ cell carcinoma in situ among individuals with intersex conditions and abnormalities of chromosomal number 17 . These data support a role for KITLG in TGCT susceptibility. Furthermore, loss of the transmembrane form of Kitl, which leads to decreased PGC number, has been identified as a TGCT susceptibility locus in the 129/Sv mouse 18 . In humans, activating mutations of KIT are the most common somatic point mutations in TGCT, present in 25% of seminomas, although rarely identified in nonseminomas 19 . Thus, both germline variation and somatic mutations in the KITLG-KIT signaling pathway are associated with TGCT. In addition, KITLG-KIT signaling has an important role in male fertility 20 , and mutations in Kitl lead to decreased germ cell number. Our findings suggest that the reported epidemiological association between TGCT and male infertility 21 may be due, in part, to a common genetic basis.
As KITLG has a role in determining level of pigmentation 22 , we postulated that inherited variation at this locus could provide a genetic explanation for the observed differences in TGCT incidence in whites and blacks. KITLG has undergone strong positive selection in the European and East Asian populations, with an extended haplotype of 400 kb 23 . Data from HapMap phase 3 show significant differences (P ¼ 4.3 Â 10 À20 ) in the frequency of the risk alleles of KITLG (rs3782179 and rs4474514) when comparing the CEU (major allele frequency ¼ 0.80) and ASW (African ancestry in Southwest United States: major allele frequency ¼ 0.25) populations 10 . This finding suggests that inherited variation in KITLG may explain, in part, the observed differences in TGCT incidence between whites and blacks.
We also observed an association between TGCT risk and variation at 5q31 just downstream of SPRY4. As with KITLG, the major allele was associated with increased risk. SPRY4 is one of a family of four genes (SPRY1-4) that have been implicated as negative regulators of the RAS-ERK-MAPK signaling pathway in response to growth factors 24 . Expression analyses and tumor studies have shown that SPRY4 is the most significantly downregulated gene when KIT signaling is inhibited by imatinib mesylate in gastrointestinal stromal tumors, supporting a functional relationship between the two proteins 12 .
In summary, our results demonstrate that common genetic variants at the 12p22 and 5q31 loci are associated with TGCT and strongly implicate KITLG as a susceptibility gene in the pathogenesis of TGCT. In addition, these observations may explain, in part, two important features of the disease: the increased incidence in whites and the epidemiological association with male infertility.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. Analyses reflect the replication set only.
a OR for heterozygous carriage of risk allele compared to homozygous carriage of non-risk allele. b OR for homozygous carriage of risk allele compared to homozygous carriage of nonrisk allele.
ONLINE METHODS
Genome-wide association study. For the discovery phase, we initially selected 353 individuals with TGCT seen at UPHS (n ¼ 303) and FCCC (n ¼ 50); all cases were from the Philadelphia region. TGCT cases from UPHS were from an ongoing clinic-based case-control study of genetic susceptibility of TGCT for which study participants were asked to complete a self-administered questionnaire that elicited information on known and presumptive risk factors for TGCT. TGCT cases from FCCC were obtained from the Biosample Repository Facility, which collects and stores blood samples and obtains information on family history of cancer, risk factors and demographics from participating subjects. We classified each individual with TGCT according to the histological diagnosis of his tumor: seminoma or nonseminoma (including yolk sac, choriocarcinoma, embryonal, teratoma and mixed cell type TGCT) germ cell tumor. Only those with primary disease in the testis were included. Male controls (n ¼ 932) were selected from PennCATH, a UPHS singlecenter, hospital-based study of angiographic coronary artery disease (CAD) in almost 4,000 subjects undergoing cardiac catheterization. This study investigates the association of biochemical and genetic factors for CAD and its risk factors 25 ; information on personal history of cancer was not collected. All controls were from the Philadelphia region, 90% were 46 years or older and had already passed the peak age of TGCT development. On the basis of available age-specific TGCT rates, we estimated that only four TGCT cases would be expected to have arisen in this control group 1 . It is unlikely that this potential small misclassification of phenotype would have biased results appreciably.
Controls had been genotyped previously using the Affymetrix GenomeWide Human SNP Array 6.0 platform and had passed genotyping quality controls measures analogous to those used for TGCT cases (see below).
We used the Affymetrix Genome-Wide Human SNP Array 6.0 to obtain genotypes for TGCT cases. We used the Birdseed algorithm to determine genotypes for the combined TGCT case and CAD control sample set 26 . Among the 353 case samples, 18 subsequently were excluded for not meeting case eligibility (two Leydig cell tumors, one female germ cell tumor erroneously coded as TGCT, 15 non-TGCT samples), and 11 replicate samples with lower genotyping call rates were excluded. Of the 324 unique samples from TGCT cases, 19 (5.9%) were excluded because of a low (o95%) genotyping call rate, 8 (2.5%) because of lower than expected genotypic heterozygosity across called markers (F ST Z 0.06) and 20 (6.2%) because of Asian or African ancestry as determined by multidimensional scaling (MDS) 27 ; no cases were excluded for cryptic relatedness (proportion of genotypes identical by descent for all cases was o0.20). Among the 932 CAD controls, 13 were excluded because of female or ambiguous sex.
After exclusion of 224,705 (24.7%) markers with a minor allele frequency (in the total sample) o0.05, 1,594 (0.2%) that deviated from Hardy-Weinberg equilibrium (HWE; P o 1 Â 10 À7 ), 71,978 (7.9%) with an individual genotype call rate o0.95 and 233 (0.03%) invalid markers, 611,112 markers remained in the discovery phase.
To further investigate potential bias that could arise from our choice of control group, we compared the minor allele frequencies of markers brought into replication between those controls with verified coronary heart disease (n ¼ 700) and those without (n ¼ 219). We noted no statistically significant differences for the six markers, nor did we observe differences when comparing the PennCath study subjects to population-based controls used in the replication phase (data not shown).
Replication study. To replicate findings of the discovery phase, we used 371 cases, 860 controls and 204 sets of mothers and fathers of cases from a population-based case-control study of TGCT in western Washington. Methods for recruitment of TGCT cases and parents in this study previously have been published 28 . Briefly, all cases had first, primary TGCT diagnosed between 1999 and 2007 and were residents of three urban counties of western Washington aged 18 to 44 years at diagnosis. Control subjects did not have a personal history of TGCT and were frequency-matched on age and ascertained from the general population of the three counties using random digit telephone dialing.
Family history of TGCT among first-degree relatives and personal history of cryptorchidism was ascertained through self-administered questionnaires. Only cases and controls who self-identified as white, non-Hispanic were included in the replication study.
Genotyping was accomplished using predesigned TaqMan SNP Genotyping Assays according to manufacturer's specifications. Genotyping was run in duplicate for 1,034 marker pairs (an average of 172 sample pairs per each of the six markers in replication). In total, six (0.58%) calls were discordant; the Spearman correlation coefficient was 40.99. Genotyping calls were made without knowledge of case or duplicate status. We also regenotyped the majority (94-99%) of TGCT cases from the discovery phase for markers in Table 2 . Concordance between genotype calls obtained from the Affymetrix chip and TaqMan assays for these four makers was 100%.
For both the genome-wide scan and replication study, all participants provided written informed consent approved by their local institutional review boards.
Statistical analysis. For the discovery phase, we used PLINK software to adjust for missing genotypes and calculate rates of heterozygosity 29 . Population stratification was assessed using multi-dimensional scaling (MDS) methods and all markers were tested for HWE. PLINK also was used to determine genotypic associations among the 277 TGCT cases and 919 CAD controls. We assessed statistical significance using Fisher's exact test, and for top hits we determined ORs and 95% CIs for the per-allele, heterozygous and homozygous effects of the minor allele (Supplementary Table 1) .
Imputation was conducted using a computationally efficient hidden Markov model-based algorithm as implemented in software MACH 30 . MACH combines our genotyped data with phased chromosomes from the HapMap CEU samples and then infers the unknown genotypes in the study sample probabilistically by searching for similar stretches of flanking haplotype in the HapMap CEU reference sample. We analyzed only markers that passed the following imputation quality control criteria: R 2 4 0.3 and MAF 4 0.05 in both cases and controls. To account for uncertainty involved in the imputation, we analyzed case-control associations for imputed SNP markers using software SNPTEST 31 .
For the replication phase, analyses were conducted using SAS v9.1.3. We used unconditional logistic regression to determine per-allele associations and associations of homozygous and heterozygous carriage of risk alleles with case status (overall and among specified subgroups), and present unadjusted ORs because age was not a confounder in our data. We assessed trend across genotype categories by the Cochran-Armitage test for trend.
Models containing markers coded on an ordinal scale (additive model) and a cross-product term were made to test for marker-marker interaction. To estimate and compare the associations within TGCT subtypes, we used multinomial logit models to obtain simultaneously the OR and 95% CI for the association between markers and each level of outcome after adjusting for age.
URLs. PLINK, http://pngu.mgh.harvard.edu/purcell/plink/.
